

钙泊三醇倍他米松软膏外用治疗寻常型银屑病的疗效、安全性及对患者生活质量的影响

[立即下载](#)

## Efficacy, safety and quality of life of topical calcipotriol betamethasone dipropionate in treatment of psoriasis vulgaris

马莉;黄岚;黄琼;杨勤萍;

### 摘要:

目的研究钙泊三醇倍他米松软膏外用治疗稳定期寻常型银屑病患者的临床疗效、安全性及对患者生活质量的影响。方法采用随机、双盲、阳性药物平行对照的临床试验,共入组80例寻常型银屑病患者,随机纳入试验组或对照组,疗程4周。试验组早晨外用模拟剂软膏基质,晚间外用钙泊三醇倍他米松软膏;对照组早晚外用卡泊三醇软膏。于首次用药后1、2、4周末观察临床疗效及安全性。结果治疗4周末试验组有效率76%(29/38)高于对照组(42%,16/38),皮肤病生活质量指数(DLQI)的下降值也大于对照组,差异均有非常显著意义( $P<0.01$ )。治疗1、2周末,试验组银屑病皮损面积和严重程度指数(PASI)较基线下降百分比大于对照组( $P<0.05$ );治疗1、2、4周末,试验组皮损总面积占体表面积百分比及患者视觉模拟评分(VAS)的改善均优于对照组( $P<0.05$ 或 $P<0.01$ )。两组均无严重不良事件发生,试验组和对照组药物不良反应发生率无显著差异(20%vs.28%, $P>0.05$ )。结论钙泊三醇倍他米松软膏治疗稳定期寻常型银屑病起效快、疗效好、用药安全方便,并可显著提高患者生活质量。

关键词: 银屑病;;卡泊三醇;;倍他米松;;钙泊三醇倍他米松软膏;;随机对照试验

基金项目:

通讯作者: 马莉;

**Email:**

### 参考文献:

- [1]KIMBALL AB,JACOBSON C,WEISS S,et al.The psycho-social burden of psoriasis[J].Am J Clin Dermatol,2005,6(6):383-392.
- [2]RAPP SR,FELDMAN SR,EXUM ML,et al.Psoriasis causes as much disability as other major medical diseases[J].J Am Acad Dermatol,1999,41(3 Pt 1):401-407.
- [3]NORRIS DA.Mechanisms of action of topical therapies and the rationale for combination therapy[J].J Am Acad Dermatol,2005,53(1 Suppl 1):S17-S25.
- [4]CHARAKIDA A,DADZIE O,TEIXERIA F,et al.Calcipotriol/betamethasone dipropionate for the treatment of psoriasis[J].Expert Opin Pharmacol,2006,7(5):597-606.

扩展功能

● 本文信息

[PDF\(237K\)](#)

[参考文献](#)

● 服务与反馈

[引用本文](#)

● 本文关键词相关文章

[银屑病](#)

[卡泊三醇](#)

[倍他米松](#)

[钙泊三醇倍他米松软膏](#)

[随机对照试验](#)

● 本文作者相关文章

[马莉](#)

[黄岚](#)

[黄琼](#)

[杨勤萍](#)

● 中国知网

[马莉](#)

[黄岚](#)

[黄琼](#)

[杨勤萍](#)

- [5]McCORMACK PL.Calcipotriol/betamethasone dipropionate:areview of its use in the treatment of psoriasis vulgaris of the trunk,limbs and scalp[J].Drugs,2011,71(6):709-730.
- [6]刘承煌,方栩.银屑病[M]//王侠生,廖康煌,杨国亮.皮肤病学.上海:上海科学技术文献出版社,2005:505-516.
- [7]RABIN F,BHUIYAN SI,ISLAM T,et al.Psychiatric and psychological comorbidities in patients with psoriasis—a review[J].Mymensingh Med J,2012,21(4):780-786.
- [8]NELSON PA,CHEW-GRAHAM CA,GRIFFITHS CE,et al.Recognition of need in health care consultations:a qualitative study of people with psoriasis[J].Br J Dermatol,2013,168(2):354-361.
- [9]VAKIRLIS E,KASTANIS A,IOANNIDES D.Calcipotriol/betamethasone dipropionate in the treatment of psoriasis vulgaris[J].Ther Clin Risk Manag,2008,4(1):141-148.
- [10]ANSTEY AV,KRAGBALLE K.Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment[J].Int J Dermatol,2006,45(8):970-975.
- [11]KRAGBALLE K,van de KERKHOF PC.Consistency of data in six phase III clinical studies of two-compound product containing calcipotriol and betamethasone dipropionate ointment for the treatment of psoriasis[J].J Eur Acad Dermatol Venerol,2006,20(1):39-44.
- [12]SARACENO R,ANDREASSI L,AYALA F,et al.Efficacy,safety and quality of life of calcipotriol/betamethasone dipropionate(Dovobet) versus calcipotriol(Daivonex) in the treatment of psoriasis vulgaris:a randomized,multicentre,clinical trial[J].J Dermatolog Treat,2007,18(6):361-365.
- [13]van de KERKHOF PC.The impact of a two-compound product containing calcipotriol and betamethasone dipropionate(Daivobet/Dovobet) on the quality of life in patients with psoriasis vulgaris:a randomized controlled trial[J].Br J Dermatol,2004,151(3):663-668.

Copyright by 中国新药与